Table 3.
Study group | mtDNAcnb | % iAs | n | β1 (95% CI)c | p-valuec | p-valued |
---|---|---|---|---|---|---|
Andes | 0.56 | < 11 | 122 | −0.018 (−0.076 to 0.039) | 0.53 | 0.013 |
0.58 | ≥11 | 122 | 0.084 (0.022 to 0.15) | 0.0080 | ||
Chaco | 0.76 | < 17 | 80 | 0.012 (−0.020 to 0.044) | 0.45 | 0.82 |
0.93 | >17 | 79 | 0.028 (0.0019 to 0.054) | 0.036 | ||
% DMA | ||||||
Andes | 0.58 | < 80.9 | 122 | 0.076 (0.017 to 0.13) | 0.011 | 0.0083 |
0.56 | ≥80.9 | 122 | −0.030 (−0.092 to 0.031) | 0.33 | ||
Chaco | 0.94 | < 71.1 | 79 | 0.027 (0.0038 to 0.049) | 0.023 | 0.83 |
0.77 | ≥71.1 | 80 | 0.020 (−0.038 to 0.079) | 0.49 |
U-As referred to as sum of urinary arsenic metabolites.
Presented as median relative values of mtDNAcn.
Log2-mtDNAcn = α + β1 × U-As (per 100 μg/L) + β2 × age + β3 × gender.
p-value for interaction (β4) from the equation: Log2-mtDNAcn = α + β1 × U-As (per 100 μg/L) + β2 × age + β3 × gender + β4 × (U-As × < and > median %iAs/%MMA/%DMA).